Bladder cancer updates from the first half of 2026

Zoldonrasib plus daraxonrasib targets KRAS G12D in metastatic pancreatic cancer with promising early results

The impact of disease burden: Understanding patient priorities in aRCC

P-32 microparticle brachytherapy plus FOLFIRINOX shows promising local control in unresectable pancreatic cancer

Therapeutic mammoplasty: An advanced oncoplastic breast surgery technique

Talquetamab plus daratumumab with or without pomalidomide improves PFS in r/r multiple myeloma

The evolving treatment landscape in immune thrombocytopenia

Highlights from APCCC 2026

ASCO 2026: Updates in bladder cancer

ASCO 2026: Updates in renal cancer

ASCO 2026: Updates in testicular, germ cell and rare genitourinary cancer

First-in-class switchable allogeneic CAR-T therapy shows promising activity in relapsed or refractory AML